143 related articles for article (PubMed ID: 11464037)
1. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction.
Dula E; Bukofzer S; Perdok R; George M;
Eur Urol; 2001 May; 39(5):558-3; discussion 564. PubMed ID: 11464037
[TBL] [Abstract][Full Text] [Related]
2. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction.
Von Keitz AT; Ströberg P; Bukofzer S; Mallard N; Hibberd M
BJU Int; 2002 Mar; 89(4):409-15. PubMed ID: 11872034
[TBL] [Abstract][Full Text] [Related]
3. An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction.
Mulhall JP; Bukofzer S; Edmonds AL; George M;
Clin Ther; 2001 Aug; 23(8):1260-71. PubMed ID: 11558862
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group.
Dula E; Keating W; Siami PF; Edmonds A; O'neil J; Buttler S
Urology; 2000 Jul; 56(1):130-5. PubMed ID: 10869641
[TBL] [Abstract][Full Text] [Related]
5. Apomorphine: an update of clinical trial results.
Heaton JP
Int J Impot Res; 2000 Oct; 12 Suppl 4():S67-73. PubMed ID: 11035390
[TBL] [Abstract][Full Text] [Related]
6. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction.
Pavone C; Curto F; Anello G; Serretta V; Almasio PL; Pavone-Macaluso M
J Urol; 2004 Dec; 172(6 Pt 1):2347-9. PubMed ID: 15538264
[TBL] [Abstract][Full Text] [Related]
7. Oral treatment of erectile dysfunction with apomorphine SL.
Altwein JE; Keuler FU
Urol Int; 2001; 67(4):257-63. PubMed ID: 11741126
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men.
Gontero P; D'Antonio R; Pretti G; Fontana F; Panella M; Kocjancic E; Allochis G; Frea B
Int J Impot Res; 2005; 17(1):80-5. PubMed ID: 15510184
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates.
Fagan TC; Buttler S; Marbury T; Taylor A; Edmonds A;
Am J Cardiol; 2001 Oct; 88(7):760-6. PubMed ID: 11589843
[TBL] [Abstract][Full Text] [Related]
10. A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction.
Perimenis P; Gyftopoulos K; Giannitsas K; Markou SA; Tsota I; Chrysanthopoulou A; Athanasopoulos A; Barbalias G
Int J Impot Res; 2004 Feb; 16(1):2-7. PubMed ID: 14963464
[TBL] [Abstract][Full Text] [Related]
11. Tolerability and safety of apomorphine SL (Ixense (TM) ).
Montorsi F
Int J Impot Res; 2003 Apr; 15 Suppl 2():S7-9. PubMed ID: 12825097
[TBL] [Abstract][Full Text] [Related]
12. Apomorphine sublingual as primary or secondary treatment for erectile dysfunction in patients with spinal cord injury.
Strebel RT; Reitz A; Tenti G; Curt A; Hauri D; Schurch B
BJU Int; 2004 Jan; 93(1):100-4. PubMed ID: 14678378
[TBL] [Abstract][Full Text] [Related]
13. Inhalation device allows novel administration of apomorphine in men with erectile dysfunction-efficacy and safety findings.
Riley A; Main M; Morgan F
J Sex Med; 2010 Apr; 7(4 Pt 1):1508-17. PubMed ID: 19845547
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of apomorphine SL (Uprima).
Bukofzer S; Livesey N
Int J Impot Res; 2001 Aug; 13 Suppl 3():S40-4. PubMed ID: 11477491
[TBL] [Abstract][Full Text] [Related]
15. Evaluating dose regimens of apomorphine, an open-label study.
Kongkanand A; Opanuraks J; Tantiwongse K; Choeypunt N; Tantiwong A; Amornvejsukit T
Int J Impot Res; 2003 Apr; 15 Suppl 2():S10-2. PubMed ID: 12825098
[TBL] [Abstract][Full Text] [Related]
16. Effects of visual sexual stimuli and apomorphine SL on cerebral activity in men with erectile dysfunction.
Hagemann JH; Berding G; Bergh S; Sleep DJ; Knapp WH; Jonas U; Stief CG
Eur Urol; 2003 Apr; 43(4):412-20. PubMed ID: 12667723
[TBL] [Abstract][Full Text] [Related]
17. Characterising the benefit of apomorphine SL (Uprima) as an optimised treatment for representative populations with erectile dysfunction.
Heaton JP
Int J Impot Res; 2001 Aug; 13 Suppl 3():S35-9. PubMed ID: 11477490
[TBL] [Abstract][Full Text] [Related]
18. Key issues from the clinical trials of apomorphine SL.
Heaton JP
World J Urol; 2001 Feb; 19(1):25-31. PubMed ID: 11289567
[TBL] [Abstract][Full Text] [Related]
19. Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder.
Caruso S; Agnello C; Intelisano G; Farina M; Di Mari L; Cianci A
Urology; 2004 May; 63(5):955-9. PubMed ID: 15134988
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of daily intake of apomorphine SL in men affected by erectile dysfunction and mild hyperprolactinemia: a prospective, open-label, pilot study.
Caruso S; Intelisano G; Farina M; DiMari L; Agnello C; Giammusso B
Urology; 2003 Nov; 62(5):922-7. PubMed ID: 14624921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
